Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Sponsor: Arcellx, Inc.
Summary
A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-04-30
Completion Date
2028-04
Last Updated
2026-02-25
Healthy Volunteers
No
Conditions
Interventions
anito-cel
Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain
Standard Lymphodepletion regimen
Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion
Locations (13)
UCLA Medical Center
Los Angeles, California, United States
University of California, Irvine
Orange, California, United States
Stanford Hospital
Palo Alto, California, United States
University of South Florida - Carol and Frank Morsani Center of Advanced Healthcare
Tampa, Florida, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
University of Minnesota Delaware Clinical Research Unit
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Columbia University Irving Medical Center
New York, New York, United States
Ohio State University
Columbus, Ohio, United States
Oregon Health & Science University (OHSU)
Portland, Oregon, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Houston Methodist Hospital
Houston, Texas, United States